High remission rate in T-cell prolymphocytic leukemia with CAMPATH-1H.

@article{Dearden2001HighRR,
  title={High remission rate in T-cell prolymphocytic leukemia with CAMPATH-1H.},
  author={Claire Dearden and Estella Matutes and Bruno Cazin and Geir Erland Tj{\o}nnfjord and Ant{\'o}nio Parreira and Benet Nomdedeu and Pietro Leoni and Fiona J. Clark and Deepti H Radia and Saad M. B. Rassam and Tony Roques and Nicolas Ketterer and Vasantha Brito‐Babapulle and M J S Dyer and Daniel Catovsky},
  journal={Blood},
  year={2001},
  volume={98 6},
  pages={
          1721-6
        }
}
T-cell prolymphocytic leukemia (T-PLL) is a chemotherapy-resistant malignancy with a median survival of 7.5 months. Preliminary results indicated a high remission induction rate with the human CD52 antibody, CAMPATH-1H. This study reports results in 39 patients with T-PLL treated with CAMPATH-1H between March 1993 and May 2000. All but 2 patients had received prior therapy with a variety of agents, including 30 with pentostatin; none achieved complete remission (CR). CAMPATH-1H (30 mg) was… Expand
T-cell prolymphocytic leukemia
TLDR
T-cell prolymphocytic leukemia is a rare aggressive post-thymic malignancy with poor response to conventional treatment and short survival, and strategies using both autologous and allogeneic stem cell transplantation are currently being explored. Expand
Allogeneic hematopoietic cell transplantation in T-cell prolymphocytic leukemia: A single-center experience.
TLDR
Allo-HCT is an effective treatment for T-PLL and patients must be evaluated for their candidacy for allo- HCT as soon as the diagnosis is confirmed. Expand
B- and T-cell prolymphocytic leukemia: antibody approaches.
  • C. Dearden
  • Medicine
  • Hematology. American Society of Hematology. Education Program
  • 2012
TLDR
The role of allogeneic transplantation with nonmyeloablative conditioning needs to be explored further in both T- and B-PLL to broaden the patient eligibility for what may be a curative treatment. Expand
Dual dependence on BCL2 and MCL1 in T-cell prolymphocytic leukemia.
TLDR
An in vitro analysis of a patient with refractory T-PLL who received venetoclax monotherapy and show dual dependence on BCL2 and MCL1 is reported, suggesting that concurrent inhibition of antiapoptotic proteins may provide more effective therapy. Expand
How I treat prolymphocytic leukemia.
TLDR
The role of allogeneic transplant with nonmyeloablative conditioning needs to be explored further in both T- and B-cell PLL to broaden the patient eligibility for what may be a curative treatment. Expand
Cytomegalovirus viremia during Campath-1H therapy for relapsed and refractory chronic lymphocytic leukemia and prolymphocytic leukemia.
TLDR
Cytomegalovirus viremia may be a significant infectious complication during Campath-1H therapy and should be investigated further in future studies. Expand
Allogeneic hematopoietic cell transplant for prolymphocytic leukemia.
  • M. Kalaycio, M. Kukreja, +13 authors M. Arora
  • Medicine
  • Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
  • 2010
TLDR
The small patient population prohibited prognostic factor analysis, but these data support consideration of allotransplant for PLL and further study of a larger population of patients is needed. Expand
Alemtuzumab for relapsed and refractory erythrodermic cutaneous T-cell lymphoma: a single institution experience from the Robert H. Lurie Comprehensive Cancer Center
TLDR
An open-label clinical trial and the clinical use of alemtuzumab in 19 heavily pretreated patients with advanced erythrodermic cutaneous T-cell lymphomas (CTCL) with acceptable toxicities are presented. Expand
Peripheral T-cell lymphomas: diagnosis and management.
TLDR
The way in which monoclonal antibodies work indicate that they may be particularly useful in treating patients who have minimal residual disease, and, in this setting, facilitate stem cell transplantation, suggests that Campath-1H should be moved to first line therapy in this aggressive disease. Expand
How I treat How I treat prolymphocytic leukemia
Tand B-cell subtypes of prolymphocytic leukemia (PLL) are rare, aggressive lymphoid malignancies with characteristic morphologic, immunophenotypic, cytogenetic, and molecular features. Recent studiesExpand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 22 REFERENCES
Treatment of T-cell prolymphocytic leukemia with human CD52 antibody.
  • R. Pawson, M. Dyer, +7 authors D. Catovsky
  • Medicine
  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 1997
TLDR
CAMPATH-1H alone is not sufficient for long-term remissions, and the role of autologous stem-cell transplantation needs further investigation, but it represents a significant improvement over other types of therapy. Expand
The role of pentostatin in the treatment of T-cell malignancies: analysis of response rate in 145 patients according to disease subtype.
TLDR
It is concluded that DCF is effective as a single agent in T-PLL, Sézary syndrome, and LGL leukemia, but has low activity in other T-cell disorders. Expand
Subcutaneous CAMPATH‐1H in fludarabine‐resistant/relapsed chronic lymphocytic and B‐prolymphocytic leukaemia
TLDR
Seven patients with B‐cell leukaemia who were treated with CAMPATH‐1H — a genetically reshaped CD52 monoclonal antibody, administered subcutaneously three times a week for 6–12 weeks — achieved complete remission and three patients with CLL attained PR; two of the latter were retreated. Expand
Humanized CD52 monoclonal antibody campath‐1H as first‐line treatment in chronic lymphocytic leukaemia
TLDR
Campath‐1H is a highly effective and well‐tolerated agent in patients with previously untreated CLL and further studies are warranted. Expand
Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia. European Study Group of CAMPATH-1H Treatment in Chronic Lymphocytic Leukemia.
TLDR
CAMPATH-1H had significant activity in patients with advanced and chemotherapy-resistant CLL, and the most pronounced effects were noted in blood, bone marrow, and spleen. Expand
CAMPATH-1H monoclonal antibody in therapy for previously treated low-grade non-Hodgkin's lymphomas: a phase II multicenter study. European Study Group of CAMPATH-1H Treatment in Low-Grade Non-Hodgkin's Lymphoma.
TLDR
CAMPATH-1H had a significant but limited activity in patients with advanced, heavily pretreated NHL, and the most pronounced effects were noted in the blood and bone marrow and in Patients with mycosis fungoides. Expand
Indolent course as a relatively frequent presentation in T‐prolymphocytic leukaemia
TLDR
T‐PLL may start as an indolent disease similar to that reported in ataxia telangectasia, and in this rare genetic disorder, some patients develop stable T‐cell clones which progress toward T‐P LL‐like leukaemia. Expand
In vivo CAMPATH-1H prevents graft-versus-host disease following nonmyeloablative stem cell transplantation.
TLDR
This study demonstrates that this nonmyeloablative preparative regimen is associated with durable engraftment, minimal toxicity, and low incidence of GVHD. Expand
REMISSION INDUCTION IN NON-HODGKIN LYMPHOMA WITH RESHAPED HUMAN MONOCLONAL ANTIBODY CAMPATH-1H
TLDR
A genetically reshaped human IgG1 monoclonal antibody (CAMPATH-1H) was used to treat two patients with non-Hodgkin lymphoma and might have an important use in the treatment of lymphoproliferative disorders and additionally as an immunosuppressive agent. Expand
Treatment of T prolymphocytic leukemia with allogeneic bone marrow transplantation
TLDR
A 47-year-old male with refractory T-PLL who was treated with high-dose chemoradiotherapy and allogeneic bone marrow transplantation from an HLA-matched sibling achieves complete remission and remains in remission 3 years after the transplant. Expand
...
1
2
3
...